We are live on ! Find out more
PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

51 hedge funds and large institutions have $118M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more capital invested

Capital invested by funds: $77.3M → $118M (+$41.2M)

12% less funds holding

Funds holding: 58 → 51 (-7)

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

39% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 18

Holders
51
Holders Change
-7
Holders Change %
-12.07%
% of All Funds
1%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
14
Reduced
16
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
+$1.85M
2
FCM
Farallon Capital Management
California
+$791K
3
BCM
Bridgeway Capital Management
Texas
+$718K
4
BlackRock
BlackRock
New York
+$328K
5
ECM
ExodusPoint Capital Management
New York
+$74.8K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$3.4M
2
RSCM
Rock Springs Capital Management
Maryland
-$1.2M
3
CS
Candriam SCA
Luxembourg
-$440K
4
Millennium Management
Millennium Management
New York
-$250K
5
Renaissance Technologies
Renaissance Technologies
New York
-$234K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
51
Cormorant Asset Management
Massachusetts
– -$3.4M -816,448 Closed
CS
52
Candriam SCA
Luxembourg
– -$440K -105,423 Closed
Millennium Management
53
Millennium Management
New York
– -$250K -60,146 Closed
Renaissance Technologies
54
Renaissance Technologies
New York
– -$234K -56,200 Closed
AA
55
ALPS Advisors
Colorado
– -$233K -55,856 Closed
SSA
56
Schonfeld Strategic Advisors
New York
– -$220K -52,700 Closed
OAM
57
Oxford Asset Management
United Kingdom
– -$113K -27,040 Closed
JG
58
Jefferies Group
New York
– -$104K -24,822 Closed
VEA
59
Virtus ETF Advisers
New York
– -$91K -21,738 Closed
EIM
60
Essex Investment Management
Massachusetts
– -$83K -20,000 Closed
LI
61
Leap Investments
Illinois
– -$75K -17,919 Closed
WG
62
Winton Group
United Kingdom
– -$50K -11,990 Closed
EMG
63
Ellington Management Group
Connecticut
– -$45K -10,800 Closed
RhumbLine Advisers
64
RhumbLine Advisers
Massachusetts
– -$42K -10,182 Closed
GT
65
Glenmede Trust
Pennsylvania
– -$20 -5,000 Closed
CAGAS
66
Capital Advisory Group Advisory Services
Minnesota
– -$12K -2,800 Closed
Victory Capital Management
67
Victory Capital Management
Texas
– -$11K -2,630 Closed
IUHSA
68
Itau Unibanco Holding S.A.
Brazil
– -$6K -432 Closed
OSAM
69
O'Shaughnessy Asset Management
Connecticut
– +$8 +2 New
1 2
3

PHAS Hedge Fund Activity: Q4 2019 in Review

51 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q4 2019, worth a combined $118M — up 53% from $77.3M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PHAS and 11 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 14 added.

The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $1.85M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $3.4M sold.

  • 51 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q4 2019, down from 58 in Q3 2019.
  • Funds reported $118M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q4 2019, up 53% quarter-over-quarter.
  • 11 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 18 closed out, a net change of -7 holders.
  • The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was Ghost Tree Capital, an estimated $1.85M added.
  • The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Cormorant Asset Management, an estimated $3.4M sold.

Based on aggregated 13F filings for Q4 2019.